JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
Momentum girdileri (karşılaştırılabilir yöneticiler): hissedar genişliği 0.0% · pay akışı -2.2% · net yeni pozisyonlar +0.5% — formül
Tüm sahiplik rakamları: yalnızca izlenen 13F yöneticileri, adi hisse senedi pozisyonları, raporlama dönemi Q4 2025
| Çeyrek | Hissedarlar | Δ | Hisseler | Raporlanan değer | Yeni | Çıkışlar |
|---|---|---|---|---|---|---|
| Q2 2026 | 183 | +1 | 1.45B | $367.13B | +5 | −3 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | — | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | — |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | — | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | — |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | — | −2 |
| Q2 2024 | 21 | — | 161.11M | $23.53B | — | — |
| # | Yönetici | Hisseler | Δ hisseler | Değer | Ağırlıkları | Tutulan | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (pasif) | 240.35M | +1.6% | $49.74B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 2 | The Vanguard Group ✦ (pasif) | 240.35M | +1.6% | $49.74B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 3 | The Vanguard Group ✦ (pasif) | 240.35M | +1.6% | $49.74B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 4 | The Vanguard Group ✦ (pasif) | 240.35M | +1.6% | $49.74B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 5 | The Vanguard Group ✦ (pasif) | 240.35M | +1.6% | $49.74B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 6 | The Vanguard Group ✦ (pasif) | 240.35M | +1.6% | $49.74B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 7 | The Vanguard Group ✦ (pasif) | 240.35M | +1.6% | $49.74B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 8 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 9 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 10 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 11 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 12 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 13 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 14 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 15 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 16 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 17 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 18 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 19 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 20 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 21 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 22 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 23 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 24 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 25 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 26 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 27 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 28 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 29 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 30 | BlackRock ✦ (pasif) | 208.78M | +0.7% | $43.21B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 31 | State Street Global Advisors ✦ (pasif) | 133.87M | +1.3% | $27.70B | 0.9% | ▲ Add | 5 | SEC ↗ |
| 32 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 33 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 34 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 35 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 37 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 38 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 39 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 40 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 44 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 45 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 46 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 47 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 48 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 49 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 50 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 51 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 52 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 53 | JPMorgan Chase ✦ | 58.56M | -50.1% | $12.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 54 | Geode Capital Management ✦ (pasif) | 57.95M | +3.1% | $11.97B | 0.7% | ▲ Add | 7 | SEC ↗ |
| 55 | Geode Capital Management ✦ (pasif) | 57.95M | +3.1% | $11.97B | 0.7% | ▲ Add | 7 | SEC ↗ |
| 56 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 57 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 58 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 59 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 60 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 61 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 62 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 63 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 64 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 65 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 66 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 67 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 68 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 69 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 70 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 71 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 72 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 73 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 74 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 75 | Morgan Stanley ✦ | 46.33M | -4.0% | $9.59B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 76 | Norges Bank ✦ (pasif) | 33.46M | Yeni | $6.92B | 0.7% | New | 1 | SEC ↗ |
| 77 | State Farm Mutual Automobile… | 31.59M | — | $6.54B | 5.1% | n/c | 1 | SEC ↗ |
| 78 | State Farm Mutual Automobile… | 31.59M | — | $6.54B | 5.1% | n/c | 1 | SEC ↗ |
| 79 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 80 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 81 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 82 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 83 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 84 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 85 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 86 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 87 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 88 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 89 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 90 | Northern Trust Corp | 29.28M | — | $6.06B | 0.8% | n/c | 1 | SEC ↗ |
| 91 | Bank Of America Corp /De/ | 28.33M | — | $5.86B | 0.4% | n/c | 1 | SEC ↗ |
| 92 | Bank Of America Corp /De/ | 28.33M | — | $5.86B | 0.4% | n/c | 1 | SEC ↗ |
| 93 | Bank Of America Corp /De/ | 28.33M | — | $5.86B | 0.4% | n/c | 1 | SEC ↗ |
| 94 | Bank Of America Corp /De/ | 28.33M | — | $5.86B | 0.4% | n/c | 1 | SEC ↗ |
| 95 | Bank Of America Corp /De/ | 28.33M | — | $5.86B | 0.4% | n/c | 1 | SEC ↗ |
| 96 | Bank Of America Corp /De/ | 28.33M | — | $5.86B | 0.4% | n/c | 1 | SEC ↗ |
| 97 | Bank Of America Corp /De/ | 28.33M | — | $5.86B | 0.4% | n/c | 1 | SEC ↗ |
| 98 | Bank Of America Corp /De/ | 28.33M | — | $5.86B | 0.4% | n/c | 1 | SEC ↗ |
| 99 | Bank of New York Mellon Corp | 24.39M | — | $5.05B | 0.9% | n/c | 1 | SEC ↗ |
| 100 | Bank of New York Mellon Corp | 24.39M | — | $5.05B | 0.9% | n/c | 1 | SEC ↗ |
"Yöneticinin ağırlığı" = pozisyonun, ilgili yöneticinin raporlanan 13F hisse senedi değeri içindeki payı — kanaat ölçütü. ✦ = küratörlü yönetici.
Yeni alıcılar
| Norges Bank | $6.92B | 0.7% |
Çıkıldı
| Renaissance Technologies | $56.88M | idi 0.1% |
Tam piyasa bağlamı: TÜM 13F filers'ları genelinde (SEC yapılandırılmış veri, Q1 2026): 1 sahipler, 136.10K hisseler, $33,268 raporlanan. Bu, yukarıdaki takip edilen evren rakamlarından farklı, daha eski bir döneme aittir ve ikisi hiçbir zaman birbirine karıştırılmaz.
Bu menkul kıymetin takip edilen yatırımcılarının en sık birlikte elinde bulundurduğu diğer varlıklar — ortak sahiplik sayımları, temel ilişkiler değil.
Açık piyasa alımları (P)
Kapsama penceremizde açık piyasa içeriden alım işlemi yok.
Açık piyasa satışları (S)
Officer · 15.00K hisse · $3.95M
Officer, Director · 20.98K hisse · $5.50M
Officer, Director · 102.31K hisse · $26.70M
Ödüller, kullanımlar ve vergi stopajı hiçbir zaman alım veya satım olarak sayılmaz. Metodoloji
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug to treat a…
Reuters